Pengaruh Dosis Eritropoietin Fase Koreksi sebagai Drug Related Problems (DRPs) Terhadap Target Kadar Hemoglobin Pada Pasien Hemodialisis Reguler

Abstract

Patients with chronic kidney disease who undergo regular hemodialysis often experience anemia. Anemia is a serious problem of maintaining the quality of life of patients with chronic kidney disease. Anemia occurs due to reduced production of erythropoietin. Erythropoietin is a hormone that stimulates the bone marrow to produce red blood cells. The use of erythropoietin if not tightly controlled will cause complications that are bad for the patients. The purpose of this research was to determine the effect of drug related problems (DRPs) to the target dose of hemoglobin level in reguler hemodialysis patients at correction phase treated with erythropoietin. This study is a clinical study with a prospective cross-sectional design, using DRP - Registration Form V7.0 (PCNE) against fifty patients. The data were analyzed statistically by using Chi-Square test, paired T-Test sample, independent T test, SPSS version 17 program. The results of the study of fifty patients, obtained dosing less than 27 patients (100%), who did not the target hemoglobin level of 17 patients (63%). Excessive dosing of 2 patients (100%), who did not the target of hemoglobin 1 patient (50%). Based on the Chi Square test, obtained the p value < 0.05, then there is a significant relationship between the dose and target hemoglobin levels. Based on T test results, p value < 0.05, then there is a difference in hemoglobin concentration target after being given significant erythropoietin therapy between the dose of less and excess. Based on the description, it can be concluded that there is an effect of drug related problems (DRPs) related to excessive dosage; less dose to target hemoglobin level with significant value, so drug related problems (DRPs) associated dose affect the target hemoglobin level.

Patients with chronic kidney disease who undergo regular hemodialysis often experience anemia. Anemia is a serious problem of maintaining the quality of life of patients with chronic kidney disease. Anemia occurs due to reduced production of erythropoietin. Erythropoietin is a hormone that stimulates the bone marrow to produce red blood cells. The use of erythropoietin if not tightly controlled will cause complications that are bad for the patients. The purpose of this research was to determine the effect of drug related problems (DRPs) to the target dose of hemoglobin level in reguler hemodialysis patients at correction phase treated with erythropoietin. This study is a clinical study with a prospective cross-sectional design, using DRP - Registration Form V7.0 (PCNE) against fifty patients. The data were analyzed statistically by using Chi-Square test, paired T-Test sample, independent T test, SPSS version 17 program. The results of the study of fifty patients, obtained dosing less than 27 patients (100%), who did not the target hemoglobin level of 17 patients (63%). Excessive dosing of 2 patients (100%), who did not the target of hemoglobin 1 patient (50%). Based on the Chi Square test, obtained the p value < 0.05, then there is a significant relationship between the dose and target hemoglobin levels. Based on T test results, p value < 0.05, then there is a difference in hemoglobin concentration target after being given significant erythropoietin therapy between the dose of less and excess. Based on the description, it can be concluded that there is an effect of drug related problems (DRPs) related to excessive dosage; less dose to target hemoglobin level with significant value, so drug related problems (DRPs) associated dose affect the target hemoglobin level.